Honouring a legacy: Malcolm Legget MNZM
Associate Professor Dr Malcolm Legget was awarded the MNZM for services to neuroendocrine cancer care in New Zealand.
Associate Professor Dr Malcolm Legget has been awarded the MNZM in recognition of his services to neuroendocrine cancer care in Aotearoa New Zealand.
His achievements for our community include spearheading efforts to bring Gallium-68 PET-CT scanning to New Zealand, advocating for PRRT access through PHARMAC, and his decades of clinical leadership for NET patients.
NOTE: Work is underway to establish a fund to honour Malcolm and provide much-needed resources for the neuroendocrine cancer community in New Zealand.
Related resources
More like this →
SCAN 2025: New Zealand leads on access, but patients still wait
New Zealanders with NETs rarely pay for treatment and have world-leading access to PRRT – but 59% report delays, and only 37% have heard of clinical trials. The SCAN 2025 findings, in full.
Waikato clinicians publish rare renal NET case in international oncology journal
A Waikato Hospital and University of Auckland team co-authored a 2025 case report on a renal neuroendocrine tumour causing Cushing's syndrome, published in Case Reports in Oncology.
Gallium-68 Dotatate PET-CT scans now accessible onboard Mobile Imaging
Mobile Health Group and Mercy Radiology have rolled out Gallium-68 Dotatate PET-CT scans on a mobile imaging unit, bringing advanced NET diagnostics closer to home.
Lanreotide now funded in New Zealand for neuroendocrine tumours
From 1 March 2025 Pharmac funds lanreotide (Mytolac) for NETs and related conditions, giving Kiwis a second somatostatin analogue option.